Caricamento...

Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)

PURPOSE: The combination of gemcitabine plus bevacizumab produced a 21% response rate and a median survival of 8.8 months in a multicenter phase II trial in patients with metastatic pancreatic cancer. These encouraging data led Cancer and Leukemia Group B (CALGB) to conduct a double-blind, placebo-c...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Kindler, Hedy Lee, Niedzwiecki, Donna, Hollis, Donna, Sutherland, Susan, Schrag, Deborah, Hurwitz, Herbert, Innocenti, Federico, Mulcahy, Mary Frances, O'Reilly, Eileen, Wozniak, Timothy F., Picus, Joel, Bhargava, Pankaj, Mayer, Robert J., Schilsky, Richard L., Goldberg, Richard M.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Clinical Oncology 2010
Soggetti:
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2917317/
https://ncbi.nlm.nih.gov/pubmed/20606091
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.28.1386
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !